![Lisa Carson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 104 340 $ al 31/05/2026
Lisa Carson is currently Chief Financial Officer at Phio Pharmaceuticals Corp.
since 2026.
Formerly, Ms. Carson was Vice President-Finance & Controller at Prelude Therapeutics, Inc. from 2021 to 2024.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 05/02/2026 | 94.000 ( 0,81 % ) | 104 340 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Director Financiero/CFO | 09/06/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Comptroller/Controller/Auditor | 01/11/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Phio Pharmaceuticals Corp.
 Phio Pharmaceuticals Corp. BiotechnologyHealth Technology Develops RNAi-based medical technologies and therapies | Health Technology |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
